Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

Therapeutic effects of epigallocatechin-3-gallate for inflammatory bowel disease: A preclinical meta-analysis - ScienceDirect

Urokinase-type plasminogen activator receptor (uPAR) as a therapeutic target in cancer, Journal of Translational Medicine

Full article: Beta-carotene regulates the biological activity of EGF in IEC6 cells by alleviating the inflammatory process

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Frontiers Low-dose ganciclovir ameliorates dextran sulfate sodium-induced ulcerative colitis through inhibiting macrophage STING activation in mice

Frontiers Enhancing intestinal barrier efficiency: A novel metabolic diseases therapy

Targeting uPA-uPAR interaction to improve intestinal epithelial barrier integrity in inflammatory bowel disease - eBioMedicine

uPAR Antibody AF807 from R&D Systems, a Bio-Techne Brand

Intestinal Barrier Dysfunction in Inflammatory Bowel Disease: Underpinning Pathogenesis and Therapeutics

Can molecular stratification improve the treatment of inflammatory bowel disease? - ScienceDirect

uPAR, beyond regulating physiological functions, has orchestrated roles in cancer (Review)

Monogenic Intestinal Epithelium Defects and the Development of Inflammatory Bowel Disease

Pathologically catalyzed physical coating restores the intestinal barrier for inflammatory bowel disease therapy, Journal of Nanobiotechnology